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SN-38 is the active metabolite of CPT-11, a water-soluble deriva-
tive of the plant alkaloid camptothecin (CPT). Camptothecins
exhibit a wide range of anti-neoplastic activity. They exert their
cytotoxic effect through a single intracellular target, the nuclear
enzyme topoisomerase I (topo I) (Hsiang et al, 1985; Hsiang and
Liu, 1988), which relieves torsional strain introduced in the DNA
duplex by active replication and transcription. The enzyme cleaves
one of the strands of the duplex DNA, allowing the 5´-end of the
cleaved strand to rotate around the internucleotide bond of the
intact strand. Resealing of the cleaved strand after one or several
strand passages completes enzyme action (Wang, 1985; Liu,
1989). CPT and its analogues slow the relegation step of the topo I
catalytic cycle without affecting the DNA cleavage reaction. As a
result, topo I-DNA adducts (cleavable complexes) are stabilized in
the presence of CPT, resulting in single-strand DNA breaks.
Although the frequency of cleavable complexes correlates well
with cytotoxicity of CPTs, the single-strand breaks are readily
reversible upon removal of the drug and are not lethal to the cell.
This suggests the involvement of additional factors. A model that
accommodates the experimental data involves the collision of the
replication machinery with the cleavable complex (Hsiang et al,
1989), causing the replication fork to arrest and a potentially lethal
double-stranded break to occur, ultimately leading to apoptotic
cell death.
This model explains the cytotoxicity of topo I-acting drugs
towards cells in the S phase of the cell cycle. Therefore, although
topo I is expressed throughout the cell cycle, it can be expected
that topo I drugs will be phase-specific, and in clinical use
schedule-dependent. Although camptothecin analogues are under-
going extensive investigation in clinical trials, relatively little
information is available regarding the optimum schedule of these
compounds. Therapeutic advantage with prolonged or repeated
dosing schedules of topotecan and irinotecan in different mouse
xenograft models has been described by several research groups
(Kawato et al, 1991; Phillips et al, 1994; Houghton et al, 1995).
The same results were obtained with topotecan in a soft-agar
cloning system (Burris et al, 1992). In other mouse xenograft
models CPT-11 appeared not to be markedly schedule-dependent
in terms of toxicity, although the intermittent and prolonged
schedules allowed moderately higher total dosages to be adminis-
tered and were more active in this model (Bissery et al, 1996).
In addition to cytotoxic effects, CPTs cause cell cycle arrest in
G2/M at low to moderate concentrations, probably as a result of
failure to activate cdc2 kinase, an enzyme involved in phosphorla-
tion reactions required to induce mitosis, whereas at higher
concentrations arrest can also be observed in early S (Del Bino
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SM2 5NE, UKet al, 1990; Dubrez et al, 1995; Goldwasser et al, 1996). The arrest
of cells in the G1 phase of the cell cycle by the topo I inhibitor
TAN-1518 (Horiguchi et al, 1994), which has a distinct mecha-
nism from CPT’s, has been reported, and probably involves the
tumour suppressor protein p53, known to regulate the G1/S check-
point of the cell cycle and the onset of apoptosis following DNA
damage.
In this study we have investigated: (i) what concentration,
duration or exposure duration (ED; exposure ´ duration) of SN-38
treatment results in cytotoxic activity; (ii) how treatment with
SN-38 affects cell cycle distribution and whether this influences
the sensitivity of the cells; (iii) whether p53-induced cell cycle
arrest may allow cells to escape apoptosis. Experiments were
carried out with LS174T (wild-type p53) and HT29 (mutant
non-functional p53) colon adenocarcinoma cell lines.
MATERIALS AND METHODS
Cell culture
HT29 (ATTC, Manassa, VA, USA) and LS174T (ATTC) colon
adenocarcinoma cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum, penicillin 100 U ml–1
and streptomycin 100 mg ml–1 (Gibco-BRL, Paisley, UK). The
cells were incubated at 37°C in a humidified atmosphere
containing 5% carbon dioxide.
SN-38
SN-38, a kind gift from Rhone Poulenc Rohrer, France, was
dissolved in dimethylsulphoxide (DMSO; Sigma, Dorset, UK) and
stock solutions were diluted in medium just before treatment. The
final concentration of DMSO in the cell culture medium was
0.02% in all cases. The concentrations of SN-38 used for treat-
ment in 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and DNA analysis were 2, 5, 10, 20, 30, 50 and
100 ng ml–1, and in those used in p53 and DNA double-staining for
flow cytometry were 0, 6.25, 12.5, 25 and 50 ng ml–1. The drug
medium was replaced every 24 h. Detached cells were harvested
and resuspended in the fresh drug medium.
Immunoprecipitation and Western blotting
After exposure to SN-38 the cells were harvested by trypsiniza-
tion, and washed three times with ice-cold phosphate-buffered
saline (PBS). Cells that had become detached were harvested with
the trypsinized cells and all were then incubated in lysis buffer for
30 min at 4°C (50 mM Tris–HCl (pH 7.4), 250 mM sodium chlo-
ride (NaCl) 5 mM EDTA, 50 mM NaF, 10 mg ml–1 phenylmethyl-
sulphonyl fluoride, 0.5 mg ml–1 leupeptin, 2 mg ml–1 soybean
trypsin inhibitor I, 0.5 mg ml–1 aprotine, 2 mg ml–1 N-Tosyl-L-
phenylanaline chloromethyl ketone, 0.1% Triton X-100) (Sigma).
The lysate was centrifuged, and the supernatant was transferred
to a fresh microfuge tube. The lysate was pre-cleared by overnight
incubation with 100 ml of protein A/Sepharose (Pharmacia, St
Albans, UK). Protein A/Sepharose was removed by centrifugation
and the supernatant was transferred to a fresh microfuge tube.
Monoclonal antibody to p53, either Pab 240 or Pab 1620, was
added and incubated overnight. Then, 100 ml of protein
A/Sepharose was added and incubated for another hour. The
complex of protein A/Sepharose and p53 was washed three times
with lysis buffer, after which 50 ml of Laemmli buffer (62.5 mM
Tris–HCl pH 6.8, 10% (v/v) glycerol, 1% (w/v) sodium dodecyl
sulphate, 5% (v/v) 2-mercaptoethanol, 0.0025% (w/v)
bromophenol blue) (Sigma) was added.
For direct Western blots, without immunoprecipitation, washed
cells were directly lysed in Laemmli buffer. The protein samples
were boiled for 5 min and loaded on to a 7.5–15% acrylamide
gel, with a 5% stacking gel. The gels were run for 4 h at 200 V,
and were blotted on to polyvinyldifluoride (PVDF) membrane
(Bio-Rad, Hemel Hempstead, UK) for 12–16 h at 20 V.
Membranes were blocked in 5% blocking reagent (Boehringer
Mannheim, Lewes, UK) in Tween–Tris-buffered saline (TTBS,
100 mM Tris–HCl pH 7.6, 0.9% (w/v) NaCl, 0.1% (v/v) Tween)
for 1 h, and subsequently washed in TTBS (4 times 10 min). P53
and topo I blots were incubated with Pab 240 or anti-topo I
(Pharmingen, San Diego, CA, USA). The washing step was
repeated. Next the membranes were exposed to horseradish per-
oxidase rabbit anti-mouse (Dako, High Wycombe, UK). P53 and
topo I bands were visualized by the enhanced chemiluminescence
(ECL) detection system (Amersham, Little Chalfont, UK).
Topoisomerase I activity assay
Nuclear extracts were prepared as described by Rubin et al (1994).
Briefly, 5 ´ 107 cells were collected by trypsinization and washed
in ice-cold PBS and nucleus buffer (NB; 2 mM KH2PO4, 5 mM
magnesium chloride (MgCl2), 150 mM NaCl, 1 mM EGTA, 0.1 mM
dithiothreitol, 0.1 mM PMSF, pH 6.5). Cells were resuspended in
10 ml NB supplemented with 0.35% Triton X-100 and rotated for
10 min. After pelleting the nuclei they were washed in NB and
resuspended in 1 ml NB containing 0.35 M NaCl and rotated for
2 h. The suspension was centrifuged at 17 000 g for 10 min, and
700 ml glycerol was added to the supernatant and stored at –20°C.
Topoisomerase I activity in the nuclear extracts was determined
using a DNA relaxation assay. The reaction mixture (final volume
20 ml) contained 0.25 mg supercoiled pHOT1 plasmid DNA
(TopoGEN, Columbus, OH, USA), 10 mM Tris–HCl pH 7.5, 1 mM
EDTA, 0.15 M NaCl, 0.1% bovine serum albumin 0.1 mM spermi-
dine and 5% glycerol, to which a dilution of the nuclear extract
was added. The mixture was incubated at 37°C for 2 h, after which
5 ml loading buffer (5% sarkosyl, 0.125% bromophenol blue, 25%
glycerol) was added. The samples were loaded on a 1% agarose
gel in TAE buffer (40 mM Tris–HCl, 20 mM glacial acetic acid,
10 mM EDTA) and were run in 4 ´ TAE buffer for 6 h at 40 V.
After staining in water containing 0.5 mg ml–1 ethidium bromide
for 30 min and destaining in water for 30 min, the gels were
photographed on Polaroid 665 film (Sigma).
MTT assay
Cytotoxicity was determined by a modified MTT (Sigma) assay
(Carmichael et al, 1987). Cells were seeded at 3000 cells per well
in a 96-well microculture plate (Falcon, Becton-Dickinson,
Oxford, UK). After 24-h incubation the medium was replaced with
medium containing SN-38, and exposed for up to 7 days. The
plates were developed by adding 50 ml MTT at 2 mg ml–1 to each
well, and incubated for a further 3 h. The plates were centrifuged
at 450 g for 10 min, and the supernatant was carefully aspirated.
The formazan crystals were dissolved in 200 ml of DMSO, and the
absorbance at 570 nm was measured, with background correction
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test was performed four times. The results were plotted against
controls.
DNA analysis
The DNA content of the cells was determined using a rapid one-
step DNA staining technique, with the fluorescent dye propidium
iodide, and apoptotic cells were discriminated by controlled
extraction of low molecular weight DNA (Darzynkiewicz et al,
1994). Attached and detached cells were harvested and fixed
overnight in 70% ethanol. The fixative was removed by centrifu-
gation and the cells resuspended in 750 ml DNA extraction buffer,
prepared by mixing 192 parts of 0.2 M Na2HPO4 with 8 parts of
0.1 M citric acid (pH 7.8). Following a 5-min incubation at room
temperature the extraction buffer was removed by centrifugation
and cells were resuspended in staining solution, 50 mg ml–1
propidium iodide and 50 mg ml–1 Ribonuclease A (Sigma). The
cells were stained for 1 h in the dark at room temperature.
Fluorescence was measured using a FACScan (Beckton-
Dickinson) and results were analysed using Lysys II software
(Beckton-Dickinson).
P53 staining of cells for flow cytometry
The procedure was the same as for DNA analysis, but with addi-
tional steps between DNA extraction and DNA staining. The cells
were washed in nucleus buffer (150 mM NaCl, 1 mM KH2PO4,
5m M MgCl2, 1 mM EGTA, 0.2 mM dithiothreitol, 1 mM PMSF (pH
6.4), and permeabilized for 20 min in nucleus buffer supplemented
with 0.35% Triton-X (Sigma). After washing, the cells were incu-
bated in primary antibody solution (DO7 1:10, Dako) for 1 h at
room temperature. Primary antibody was removed by washing
with PBS, after which secondary antibody was added (fluorescein
isothiocyanate (FITC)-labelled anti-mouse, Sigma). The cells
were incubated for 45 min at room temperature and washed with
PBS. FITC and PI fluorescence were determined with the
FACScan (Beckton-Dickinson). Cells were gated for each phase of
the cell cycle according to the DNA profile and FITC fluorescence
was determined in each gate. FITC fluorescence in SN-38-treated
samples were expressed relative to control.
Statistical analysis
Comparisons between treatments were made by analysis of vari-
ance (ANOVA), controlling for drug concentration and exposure
duration. If the residuals from this analysis were not normally
distributed, non-parametric ANOVA was used. Where ANOVA
indicated differences between treatments, pair-wise comparisons
were made using paired t-tests (normally distributed data) or
Wilcoxon matched pairs signed ranks test (not normally distrib-
uted data).
RESULTS
P53 status, topoisomerase expression and activity
The p53 status of the HT29 and LS174T colon carcinoma cell lines
was confirmed by immunoprecipitation experiments with the
conformational antibodies Pab 240 and Pab 1620, which recognize
the mutant and wild-type conformation of p53 respectively. As
shown in Figure 1A only mutant conformation p53 was immuno-
precipitated from HT29 cells, which confirms that the R273H
mutant of p53 belongs to the class of structural mutants and is
consistent with previous in vitro data (Rolley et al, 1995), whereas
only wild-type conformation protein was precipitated from
LS174T cells. Differences in topo I content or activity of both cell
lines might influence cytotoxicity of SN-38 in these cell lines.
However, the topo I content of both cell lines was similar by
Western blot analysis of total cellular extract (Figure 1B). Topo I
activity was also very similar in these cell lines, as demonstrated
by the relaxation of supercoiled plasmid DNA (Figure 1C).
Cell cycle effects of SN-38 in HT29 cells
Changes in cell cycle distribution of HT29 cells during exposure
to SN-38 were both concentration- and duration-dependent
(P < 0.001). The G1 phase of the cell cycle was rapidly emptied,
within 24 h of exposure to concentrations ³ 5 ng ml–1 (Figure 2
A,B), with the fraction of cells in G1 remaining almost constant
throughout the experiment at approximately 10%. Cells incubated
with 2 ng ml–1 SN-38 showed no significant change in G1 popula-
tion. At 5 ng ml–1 G1 was emptied until 10–20% of the cells were
in this phase and remained at this percentage throughout the
experiments.
Cytotoxicity of SN-38 in colon adenocarcinoma cell lines 1287
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Figure 1 P53 status and topo I levels and activity in HT29 and LS174T
cells. (A) P53 western of Pab 240 and 1620 immunoprecipitated extracts,
specific for mutant and wild-type p53 respectively, of 1 ´ 106 untreated cells.
(B) Topoisomerase I Western blot of total cellular extract of 1 ´ 105 untreated
cells. (C) Relaxation of supercoiled plasmid DNA by topo I from serial
dilutions of nuclear extracts of untreated cells. Control lane contains only
plasmid DNA. SC and R supercoiled and relaxed plasmid DNAThe S phase population of exponentially proliferating HT29
cells was 21.9 ± 8.3% (Figure 2B). After 24-h incubation there
was a slight decrease in S phase occupancy in cells exposed
to 5–30 ng ml–1, which was much more apparent after 48 h at
concentrations from 5 to 50 ng ml–1. In contrast, at 100 ng ml–1 a
slight S phase accumulation could be seen at 24 h. After 48 h a
repopulating of S phase occurred up to 72 h, after which a gradual
decrease could be observed out to 168 h.
Cell cycle arrest in the G2/M phase of the cell cycle developed
within 24 h of exposure to SN-38, and accumulation continued to
a maximum at 48-h exposure (Figure 2 A,B). The maximum
extent of accumulation in the G2/M phase was reached at concen-
trations of 10 and 20 ng ml–1 (approximately 87 ± 3% of cells
arrested in G2/M). At all concentrations which showed a G2/M
block at 48 h, a rapid decrease in the G2/M population was
apparent after 48 h (Figure 2 A,B).
The percentage of apoptotic cells as depicted in Figure 2B
showed a significant increase with time and concentration
(P < 0.001). The increase in the number of apoptotic cells became
clear after 72 h, whereas up to 48 h there was little effect of SN-38
on apoptosis (Figure 2 A,B), except at the higher SN-38 concen-
trations. Apoptosis continued to increase at concentrations of
³ 5 ng ml–1 even out to 168 h. Dose effect reached plateau at
10–20 ng ml–1 with exposures over 96 h, with little additional
increase in apoptosis at higher concentrations (Figure 2B).
Induction of apoptosis was confirmed by Western blotting for Poly
ADP-ribose polymerase (PARP). The 85-kDa cleaved form of
PARP could be observed 72 h after exposure to 25 ng ml–1 SN-38
(results not shown).
Cell cycle effects of SN-38 in LS174T cells
There was a strong concentration-dependent effect of SN-38 on
the cell cycle distribution of LS174T cells (P < 0.001; Figure 2B),
however, when accounting for variation with concentration there
was no significant effect with exposure duration. At 2 ng ml–1 the
population in G1 consisted of about 35% of cells throughout the
experiment. The G1 population decreased after 24-h exposure,
with the effect being most marked at concentrations of 5–
20 ng ml–1 and a gradually smaller effect at higher concentrations
up to 100 ng ml–1 (Figure 2 A,B). After 24 h the G1 populations
remained fairly constant at each concentration.
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Figure 2 Cell cycle analysis of HT29 and LS174T cells after exposure to SN-38. Time course of cell cycle dynamics by FACS analysis of 1 ´ 104 cells,
extracted for low molecular weight DNA to discriminate apoptotic cells, stained with propidium iodide. (A) Typical DNA profiles for HT29 and LS174T cells
exposed to 10 and 100 ng ml–1 respectively. (B) Summary of the cell cycle data in HT29 and LS174T cells. Data are the averages of at least four experimentsLS174T cells showed a concentration-dependent increase in the
S phase population (Figure 2B), which was maximal at concentra-
tions of 10–20 ng ml–1 at approximately 35%, with no significant
change with time after 24 h (P > 0.05).
G2/M arrest (Figure 2B) occurred within 24 h at concentrations
of 2–10 ng ml–1 and was maximal at concentrations of 2 and
5 ng ml–1. There was little effect on the G2/M population at the
higher concentrations, and again after 24 h there was no signifi-
cant change in the G2/M population with time (P > 0.05).
A clear increase in apoptosis in LS174T cells (Figure 2B) was
apparent only at the highest concentrations (50 and 100 ng ml–1),
for which apoptosis was maximal at 72 h. No PARP cleavage
could be observed in LS174T cells exposed to 25 ng ml–1 SN-38
(results not shown).
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Figure 3 Percentage survival of HT29 and LS174T cells after exposure to SN-38. Percentage survival was assessed by the MTT assay. (A) HT29,
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Figure 4 P53 expression in the cell cycle phases of LS174T cells. P53 fluorescence relative to control in each phase of the cell cycle of LS174T cells gated
out according to DNA profile. Data are the averages of four experiments
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G2/MPercentage survival after SN-38 exposure
Although there was little effect of SN-38 on apoptosis in LS174T
cells, growth was inhibited, as can be seen in the decrease in
percentage survival (Figure 3B). At 48 h growth was inhibited at
all concentrations, and decreased with time and concentration up
to 96-h exposure after which point the time effect decreased, prob-
ably because of fewer cycling cells in the control population.
In HT29 cells there was little effect of SN-38 on the percentage
survival for the first 48 h, becoming apparent only after 48-h expo-
sure. The decrease in the percentage survival decreased with time
and concentration thereafter (P < 0.001), continuing out to 168 h.
The minimum surviving population was 21% of control in LS174T
cells, but only 5% in HT29 cells.
P53 expression
The fact that LS174T cells were retained in G1, whereas HT29
cells rapidly progressed through G1 and S before arresting in
G2/M, was an indication of the involvement of p53. To measure
p53 expression in each compartment of the cell cycle, cells were
dually stained for DNA and p53. As can be seen in Figure 4, p53
levels showed an approximate sevenfold increase relative to
control on exposure to SN-38 in the G1, S and G2/M phases of the
cell cycle. In each phase of the cell cycle p53 expression increased
with time (P < 0.001), whereas only in G1 was there an effect of
concentration on p53 expression (P = 0.01) with a concentration-
dependent decrease in p53 levels after 96 h.
In HT29 cells there was no significant change in p53 levels
(P > 0.05; results not shown). Western blot analyses of total cell
extracts confirmed the results obtained by FACS analyses; with
increased p53 levels in SN-38 (25 ng ml–1) treated LS174T cells,
but no change in HT29 cells (results not shown).
Schedule effect of SN-38 at the same ED
The fact that there was a poor correlation between ED of SN-38
and apoptosis in both HT29 (R2 = 0.49) and LS174T cells
(R2 = 0.20) indicated there might be a possible schedule effect.
Therefore we analysed the extent of apoptosis of different sched-
ules at the same ED (exposure ´ duration). In HT29 cells the more
prolonged schedules at lower concentrations were significantly
more active with respect to apoptosis than the shorter schedules at
higher concentrations (Table 1A). In LS174T cells, however, there
was a trend towards increased apoptosis in the shorter schedules at
higher concentrations, although the difference reached statistical
significance in a few cases only (Table 1B), possibly due to the
lower level of apoptosis in this cell line.
DISCUSSION
This study was designed to investigate the effect of concentration
and exposure duration on the cytotoxicity of SN-38, with par-
ticular regard to cell cycle distribution and apoptosis in cells with
different p53 status.
Although SN-38 is considered an S phase cytotoxic, it had very
little effect on apoptosis and percentage survival in HT29 cells
during the first 48 h. Exposure of HT29 cells to SN-38
Cytotoxicity of SN-38 in colon adenocarcinoma cell lines 1291
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Table 1 Schedule effect of SN-38 on apoptosis in HT29 and LS174T cells at the same ED (ED is exposure duration, exposure (ng ml–1 multiplied by duration
(h))
A HT29 Apoptosis ± SP 
ED Schedule 1 (T 3 C) Schedule 2 Schedule 3
240 9.9 (3.7–12.2) 24 ´ 10 9.0 (7.0–10.2)  48 ´ 5 15.6 (14.9–35.2)b 120 ´ 2
480 9.3 ± 4.2 24 ´ 20 6.1 ± 2.0 48  ´ 10 28.0 ± 4.1b,e 96 ´ 5
720 13.0 ± 8.8 24 ´ 30 12.3 ± 4.1 72  ´ 10 38.3 ± 5.1b,e 144 ´ 5
960 7.9 ± 2.5 48 ´ 20 30.5 ± 4.2e 96 ´ 10
1200 11.5 ± 6.5 24 ´ 50 47.2 ± 9.9d 120 ´ 10
1440 12.8 ± 3.1 48 ´ 30 13.8 ± 3.3 72  ´ 20 54.9 ± 4.4b,e 144 ´ 10
2400 10.0 ± 4.6 24 ´ 100 16.9 ± 4.4 48  ´ 50 54.1 ± 14.3b,d 120 ´ 20
2880 40.0 ± 4.0 96 ´ 30 59.0 ± 6.7d 144 ´ 20
3600 34.6 ± 4.6 72 ´ 50 57.7 ± 8.6d 120 ´ 30
4800 23.0 ± 5.4 48 ´ 100 43.3 ± 2.8d 96 ´ 50
7200 42.2 ± 2.0 72 ´ 100 67.1 ± 4.2e 144 ´ 50
B LS174T
ED Schedule 1 Schedule 2 Schedule 3
240 11.8 ± 1.6 24 ´ 10 7.0 ± 0.7a 48 ´ 5 8.9 ± 3.4 1 20 ´ 2
480 13.2 ± 1.7 24 ´ 20 10.8 ± 2.9 48 ´ 10 9.8 ± 4.5 96 ´ 5
720 16.0 ± 1.1 24 ´ 30 12.1 ± 5.6 72  ´ 10 9.3 ± 2.0d 144 ´ 5
960 9.0 ± 3.2 48 ´ 20 11.1 ± 6.4 96  ´ 10
1200 20.7 ± 0.9 24 ´ 50 8.2 ± 2.0e 120 ´ 10
1440 12.3 ± 4.4 48 ´ 30 15.8 ± 3.3 72  ´ 20 7.1 ± 3.7b 144 ´ 10
2400 26.4 ± 1.8 24 ´ 100 20.8 ± 12.3 48 ´ 50 19.0 ± 12.9a 120 ´ 20
2880 20.8 ± 12.3 96 ´ 30 14.0 ± 6.3 144 ´ 20
3600 25.4 ± 9.3 72 ´ 50 12.8 ± 1.5 120 ´ 30
4800 24.2 ± 14.8 48 ´ 100 23.4 ± 13.5 96 ´ 50
7200 35.1 ± 10.4 72 ´ 100 12.9 ± 2.1a,c 144 ´ 50
From schedule 1–3 increasing time and decreasing concentration.aSignificant difference with schedule 1, bsignificant difference with schedule 2. cP < 0.05,
dP < 0.01, eP < 0.001.concentrations of 5 ng ml–1 and higher resulted in a rapid emptying
of the G1 phase of the cell cycle, and after going through S phase,
cells accumulated in G2/M. Accumulation continued up to a
maximum at 48 h. Cells damaged during replication in the S phase
did not undergo apoptosis immediately and were allowed to
traverse the S/G2 border before arresting in G2/M. S phase arrest
at 48 h was relevant only at 100 ng ml–1, indicating that extensive
damage results in immediate arrest in this cell cycle phase. A dose-
dependent S or G2/M arrest has also been reported in cell lines
exposed to camptothecin, with cell cycle arrest in G2/M at low to
moderate concentrations, whereas at higher concentrations arrest
could also be observed in early S (Del Bino et al, 1990; Dubrez et
al, 1995; Goldwasser et al, 1996).
In spite of continued drug exposure, HT29 cells were released
from G2/M arrest, which resulted in a concomitant increase in
apoptosis and a decrease in cell survival. Thereafter the S phase
and G2/M phase depopulated with continued exposure, paralleled
by an increase in apoptosis and a decrease in cell survival. We
have observed the same pattern in ovarian cell lines with mutant or
null p53 treated with SN-38 (RH te Poele, unpublished data), and
similar results have been reported with 9-nitro and 9-amino camp-
tothecin (Pantazis et al, 1993).
In LS174T cells apoptosis developed within 24 h of exposure at
the higher concentrations and was maximal after 72-h exposure.
Although the effect of SN-38 on apoptosis was modest, cell cycle
arrest developed at all concentrations as reflected in the decrease
in percentage survival compared to a control population. The cell
cycle dynamics showed strong concentration dependence and little
variation with exposure duration, suggesting that cells were frozen
in the cell cycle, similar to the findings of Poot et al (1995) who
reported accumulation of cells in each phase of the cell cycle with
the parent compound camptothecin. At low concentrations
LS174T cells progressed through S and accumulated in G2/M, and
with increasing concentration arrested in the S phase, whereas at
the highest concentration cells were retained in G1. Cells remained
arrested for the duration of the exposure. In a continuation of these
studies we found that, when SN-38 was withdrawn after 7 days,
and LS174T cells were re-cultured in drug-free medium, cells
remained arrested in the cell cycle. Moreover, cell lines with wild-
type p53 responded in two ways to SN-38, either by undergoing
apoptosis following transient G1 arrest, or by irreversible cell
cycle arrest with phenotypical and biochemical characteristics of
replicative senescence (RH te Poele, unpublished data).
In LS174T cells the response to SN-38 was faster, and was asso-
ciated with increased expression of p53, and may involve more
efficient recognition and an intact signal transduction pathway.
This may also explain the increased sensitivity of LS174T cells to
very low concentrations of SN-38 with respect to growth arrest.
However, the fast response and increased sensitivity did not lead
to an overall increase in apoptosis and decrease in cell survival as
compared to HT29 cells. LS174T cells resisted apoptotic cell
death by SN-38 through continued p53-associated cell cycle
arrest, as opposed to the transient blockage in G2/M of HT29 cells,
and suggests the possible involvement of p53 in prolonged cell
cycle arrest in G1, S and G2/M. It has also been suggested that p53
is involved in prolonged G1 arrest in human fibroblasts after
irradiation (Di Leonardo et al, 1994).
P53-associated G1 arrest or apoptosis indicates an additional
cytotoxic mechanism of SN-38, because in G1 there is no DNA
synthesis, and it has been shown that camptothecin-stabilized
cleavable complexes are insufficient to stimulate increased p53
levels (Nelson and Kastan, 1994). The main genetic process in G1
is transcription and there is a possibility that interference in this
process by SN-38 may generate a signal to p53. This is enforced
by the observations that camptothecin causes rapid cessation of
RNA synthesis (Bendixen et al, 1990), and was shown to have
a cytotoxic mechanism that was not protected by aphidicolin
(Goldwasser et al, 1996).
There was poor correlation between ED and apoptosis in both
HT29 and LS174T cells indicating a possible schedule effect.
More detailed investigation of the effect of different regimens at
the same drug ED enforced this. Between the different schedules
the regimens with prolonged exposure were consistently more
effective in HT29 cells. An advantage with protracted schedules
has been observed before in the laboratory and the clinical setting
(Muggia et al, 1972; Kawato et al, 1991; Hochster et al, 1994;
Houghton et al, 1995; Phillips et al, 1994; Slichenmyer et al,
1994). In LS174T cells, however, the shorter schedules at higher
concentrations seemed to be more effective.
Although cells with intact p53 respond more efficiently to DNA
damage than cells with mutated p53, the sensitivity to SN-38
seems mainly determined by the degree of cell cycle progression
upon DNA damage. Cells, which do not progress through the cell
cycle due to intact cell cycle check points, appear to have a
reduced sensitivity to SN-38. A similar effect between cell cycle
arrest and resistance to camptothecin has been described for
leukaemic cell lines (Solary et al, 1996). We also found that p53
null or mutant ovarian cell lines showed transient arrest in S or
G2/M followed by apoptosis with the protracted schedules. In
tumour cells expressing wild-type p53 the situation is more
complicated. Exposure to SN-38 either results in transient G1
arrest followed by apoptosis, in which case the protracted
schedules are more active, or by undergoing permanent cell cycle
arrest, when apoptosis could only be observed at the higher doses
with short exposures (Figure 2B and RH te Poele, unpublished
data), indicating the involvement of additional factors in deter-
mining the optimal schedule in this cell type. Although the
differences between the two cell lines investigated are striking,
and are at least in part due to their difference in p53 status, the
influence of other differences between the cell lines can not be
ruled out.
In view of the results presented here a pulsed schedule may
prove more effective in LS174T cells, allowing cells to go back
into cycle before cell cycle arrest becomes irreversible and an
additional dose of drug is administered. This may also explain the
observation from some clinical trials that repeated dose schedules
were more effective (Fukuoka and Masuda, 1994; Von Hoff et al,
1994). The camptothecin derivatives topotecan or 9-amino-
camptothecin might be more useful in this setting, because of their
shorter plasma half-lives. However, considering that normal tissue
contains wild-type p53, a high-dose pulsed schedule might also
prove to be more toxic.
In contrast, continued, prolonged exposure in cells with mutant
non-functional p53 appears to be more active. The minimum
effective concentration in HT29 cells was 5–10 ng ml–1, which is
within the range of clinical relevance (Catimel et al, 1995; Canal
et al, 1996). Above these concentrations, dose effect reached
plateau with prolonged exposures. Prolonged exposure to SN-38,
when there are differences in p53 status of the tumour and the
normal tissue, might increase the therapeutic index of SN-38.
These different activities of SN-38 schedules in p53 wild-type
and mutant cells could also explain why some clinical trials
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differences in p53 status in patient tumours.
The results of this study highlight the importance of cell cycle
factors on the activity of topo I inhibitors. It can be anticipated that
proteins involved in regulation of the cell cycle and modulation of
apoptosis will play an important role in the clinical activity of
these drugs. Additionally, the optimal treatment schedule for topo
I inhibitors may be more dependent on the individual patient’s
tumour characteristics than the tumour site, suggesting a possible
role for the use of molecular factors in determining treatment
strategies.
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